Latest news with #PatelChemSpecialities
Economic Times
4 days ago
- Business
- Economic Times
Patel Chem Specialities IPO to open on July 25, price band set at Rs 82 to Rs 84 per equity share
Patel Chem Specialities' ₹58.8 crore IPO opens on July 25 and closes on July 29. Proceeds will fund a new plant, corporate needs, and expansion. Listing is set for August 1 on BSE SME. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads IPO proceeds use About Patel Chem Specialities Patel Chem Specialities will open its Initial Public Offering (IPO) on Friday, July 25. The issue comprises a fresh offer of 70,00,000 equity shares with a face value of ₹10 each. The total issue size is ₹58.80 crore at the upper price band, with the price band set at ₹82 to ₹84 per share. The market lot is 1,600 equity anchor portion will open and close on July 24. The issue will close on July 29. The expected allotment date and credit to demat accounts is on or before July 31. The listing date is August 1 and will be listed on BSE Read | The Wealth Company receives Sebi approval to commence mutual fund business The share allocation for Qualified Institutional Buyers (QIB, including Anchor) is 33,16,800 shares, for Non-Institutional Investors (NII) is 9,98,400 shares, for Retail Individual Investors is 23,31,200 shares and for market maker is 3,53,600 lead managers are Cumulative Capital Private Limited and Unistone Capital Private Limited. The registrar to the issue is MUFG Intime India Private Limited (formerly Link Intime India Private Limited).The utilization of net proceeds will be for funding capital expenditure requirement of our company, to set up plant at Indrad, Mahesana for manufacturing Croscarmellose Sodium, Sodium Starch Glycolate – Corn Starch Base & Potato Starch Base and Calcium Carboxymethylcellulose (CMC), for general corporate purposes, and for issue-related expenses."The IPO proceeds will fuel our strategic expansion and strengthen our presence in both domestic and international markets. With a growing portfolio of pharmaceutical excipients and exports to over 15 countries, we are committed to timely and customized delivery through our advanced facilities in Vatva and Talod. The upcoming facility at Indrad, Mehsana will help us meet rising demand for key products like CCS, SSG, and Calcium CMC, and support our focus on innovation and customer-driven solutions," said Bhupesh Patel, Managing Director of Patel Chem Specialities."We are proud to partner with Patel Chem Specialities Limited for their IPO journey. The company's strong foundation in pharmaceutical excipients, backed by a seasoned leadership team and robust export footprint, positions it well for sustainable growth in a global market that's increasingly leaning on reliable, high-quality ingredients. This offering marks an important milestone not just for the company, but for investors seeking value in a rapidly evolving pharmaceutical ecosystem. With the upcoming facility in Indrad, their scale and innovation potential are set to expand meaningfully," said Swapnilsagar Vithalani, Co-founder and Director, Cumulative Capital Read | NFO Insight: Capitalmind Mutual Fund's flexi cap fund opens for subscription. Will it help to manage current market volatility? Established in 2008, Patel Chem Specialities Limited is a leading manufacturer of cellulose- and starch-based pharmaceutical excipients and is known for its commitment to global quality standards, according to a press company's products are integral to drug formulation processes and comply with global quality benchmarks. With a dedicated in-house R&D facility and an experienced technical team, the company offers customized, cost-effective, and innovative specialty chemical solutions across diverse of FY25, the company has an installed production capacity of 7,200 MT per year, with a capacity utilization rate of 89%.In FY25, the company reported a strong performance with Operating Revenue of Rs 105.09 crore, EBITDA of Rs 15.27 crore with Net Profit of Rs 10.57 crore.
Time of India
4 days ago
- Business
- Time of India
Patel Chem Specialities IPO to open on July 25, price band set at Rs 82 to Rs 84 per equity share
Patel Chem Specialities will open its Initial Public Offering (IPO) on Friday, July 25. The issue comprises a fresh offer of 70,00,000 equity shares with a face value of ₹10 each. The total issue size is ₹58.80 crore at the upper price band, with the price band set at ₹82 to ₹84 per share. The market lot is 1,600 equity shares. The anchor portion will open and close on July 24. The issue will close on July 29. The expected allotment date and credit to demat accounts is on or before July 31. The listing date is August 1 and will be listed on BSE SME. Explore courses from Top Institutes in Select a Course Category Digital Marketing Data Analytics Artificial Intelligence Data Science Cybersecurity MBA Leadership Design Thinking CXO MCA Management Public Policy Technology Degree healthcare Project Management Product Management Healthcare others Others Data Science Finance PGDM Skills you'll gain: Digital Marketing Strategy Search Engine Optimization (SEO) & Content Marketing Social Media Marketing & Advertising Data Analytics & Measurement Duration: 24 Weeks Indian School of Business Professional Certificate Programme in Digital Marketing Starts on Jun 26, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Morocco: Unsold Sofas Prices May Surprise You (Prices May Surprise You) Sofas | Search Ads Search Now Also Read | The Wealth Company receives Sebi approval to commence mutual fund business The share allocation for Qualified Institutional Buyers (QIB, including Anchor) is 33,16,800 shares, for Non-Institutional Investors (NII) is 9,98,400 shares, for Retail Individual Investors is 23,31,200 shares and for market maker is 3,53,600 shares. The lead managers are Cumulative Capital Private Limited and Unistone Capital Private Limited. The registrar to the issue is MUFG Intime India Private Limited (formerly Link Intime India Private Limited). Live Events IPO proceeds use The utilization of net proceeds will be for funding capital expenditure requirement of our company, to set up plant at Indrad, Mahesana for manufacturing Croscarmellose Sodium, Sodium Starch Glycolate – Corn Starch Base & Potato Starch Base and Calcium Carboxymethylcellulose (CMC), for general corporate purposes, and for issue-related expenses. "The IPO proceeds will fuel our strategic expansion and strengthen our presence in both domestic and international markets. With a growing portfolio of pharmaceutical excipients and exports to over 15 countries, we are committed to timely and customized delivery through our advanced facilities in Vatva and Talod. The upcoming facility at Indrad, Mehsana will help us meet rising demand for key products like CCS, SSG, and Calcium CMC, and support our focus on innovation and customer-driven solutions," said Bhupesh Patel, Managing Director of Patel Chem Specialities. "We are proud to partner with Patel Chem Specialities Limited for their IPO journey. The company's strong foundation in pharmaceutical excipients, backed by a seasoned leadership team and robust export footprint, positions it well for sustainable growth in a global market that's increasingly leaning on reliable, high-quality ingredients. This offering marks an important milestone not just for the company, but for investors seeking value in a rapidly evolving pharmaceutical ecosystem. With the upcoming facility in Indrad, their scale and innovation potential are set to expand meaningfully," said Swapnilsagar Vithalani, Co-founder and Director, Cumulative Capital Private. Also Read | NFO Insight: Capitalmind Mutual Fund's flexi cap fund opens for subscription. Will it help to manage current market volatility? About Patel Chem Specialities Established in 2008, Patel Chem Specialities Limited is a leading manufacturer of cellulose- and starch-based pharmaceutical excipients and is known for its commitment to global quality standards, according to a press release. The company's products are integral to drug formulation processes and comply with global quality benchmarks. With a dedicated in-house R&D facility and an experienced technical team, the company offers customized, cost-effective, and innovative specialty chemical solutions across diverse applications. As of FY25, the company has an installed production capacity of 7,200 MT per year, with a capacity utilization rate of 89%. In FY25, the company reported a strong performance with Operating Revenue of Rs 105.09 crore, EBITDA of Rs 15.27 crore with Net Profit of Rs 10.57 crore.
